Search Results

Cellectis announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca completed the additional equity investment of $140M in Cellectis, as previously announced by Cellectis on November 1 and 15, 2023.

May 6, 2024

·

3 min read

Press Releases

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

February 24, 2025

·

4 min read

Business

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Cellectis announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market.

May 27, 2024

·

1 min read

Pharm Country

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Cellectis announced that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

May 29, 2024

·

1 min read

Business

Cellectis Reports Financial Results for First Quarter 2024

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the three-month period ending March 31, 2024.

May 28, 2024

·

19 min read

Pharm Country

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

June 28, 2024

·

1 min read